Archive for March, 2014

(PCRX) Announces FDA Approval of Additional Manufacturing Suite for EXPAREL

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL® (bupivacaine liposome injectable suspension). The suite is housed at the company’s Science Center Campus in San Diego, where EXPAREL is currently manufactured.

“We believe the approval of an additional suite to manufacture EXPAREL marks an important milestone for the company,” said Dave Stack, president, chief executive officer and chairman of Pacira. “Expansion of our manufacturing capacity will enable us to meet the growing demands of both existing and future customers seeking an EXPAREL-based multimodal pain management regimen to reduce the use of narcotics, with the ultimate goal of decreasing narcotic-related adverse events.”

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

About EXPAREL®

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.

Please see the full Prescribing Information at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about our plans and expectations regarding EXPAREL, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the indications of EXPAREL, including for nerve block and the related timing and success of an sNDA; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical studies in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; and other factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Monday, March 31st, 2014 Uncategorized Comments Off on (PCRX) Announces FDA Approval of Additional Manufacturing Suite for EXPAREL

(ACAS) Announces Purchase of 8.9M of Its Shares, Suspends Share Repurchase Program

BETHESDA, Md., March 31, 2014  — American Capital, Ltd. (Nasdaq: ACAS) (“American Capital” or the “Company”) announced today that in the first quarter of 2014, it made open market purchases of 8.9 million shares of American Capital common stock, or 3.3% of the Company’s outstanding shares as of December 31, 2013.  The shares were purchased at an average price of $15.38 per share, totaling $137 million.

Starting in the third quarter of 2011, American Capital has made open market purchases of 101.6 million shares, or 29.4% of the Company’s outstanding shares as of June 30, 2011, at an average price of $11.74 per share, totaling $1.2 billion.  Purchases starting in the third quarter of 2011 through December 2013 were $1.75 per share accretive to the Company’s $18.97 net asset value per share (“NAV”) as of December 31, 2013.  Accretion from the purchases in the first quarter of 2014 will be disclosed in the Company’s first quarter earnings release.

These share purchases were completed in accordance with the Company’s Share Repurchase and Dividend Policy. The Company’s Board of Directors has decided to suspend such purchases for an indefinite period.  As previously disclosed in the Company’s Annual Report on Form 10‑K filed with the Securities and Exchange Commission for the year ending December 31, 2013, the Company is undertaking a process to evaluate its corporate structure to determine whether that structure and the various legal, regulatory and accounting regimes under which it operates are the optimum means for the operation and capitalization of its business.  The Board has determined that it is appropriate to suspend share purchases as it considers the capital requirements of organizational changes that could result from this evaluation.

ABOUT AMERICAN CAPITAL
American Capital, Ltd. (Nasdaq: ACAS) is a publicly traded private equity firm and global asset manager.  American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate, energy & infrastructure and structured products.  American Capital manages $19 billion of assets, including assets on its balance sheet and fee earning assets under management by affiliated managers, with $93 billion of total assets under management (including levered assets).  Through an affiliate, American Capital manages publicly traded American Capital Agency Corp. (Nasdaq: AGNC) with approximately $9 billion of net book value, American Capital Mortgage Investment Corp. (Nasdaq: MTGE) with approximately $1 billion of net book value and American Capital Senior Floating, Ltd. (Nasdaq: ACSF).  From its eight offices in the U.S. and Europe, American Capital and its affiliate, European Capital, will consider investment opportunities from $10 million to $750 million.  For further information, please refer to www.AmericanCapital.com.

This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.

Monday, March 31st, 2014 Uncategorized Comments Off on (ACAS) Announces Purchase of 8.9M of Its Shares, Suspends Share Repurchase Program

(PTN) Announces Option Extension for License to Bremelanotide in Europe

CRANBURY, N.J., March 31, 2014  — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.

Palatin received a $1.0 million, non-refundable option fee under the option agreement. Subject to certain contingencies, if not exercised, the option will expire on April 30, 2014.

The option agreement is with a European specialty pharmaceutical company with pharmaceutical manufacturing, research and development, sales and marketing capabilities.  As part of the option agreement, the parties sought and received clear regulatory advice from the European Medicines Agency (EMA) on the phase 3 clinical data required for approval of bremelanotide for female sexual dysfunction in the European Union. The extension is to allow the potential optionee to complete its comprehensive market assessment, including qualitative and quantitative surveys, in selected countries.

“We believe the European Union is a significant market for female sexual dysfunction and we are pleased with the relationship with our potential European partner,” stated Carl Spana, Ph.D., President and CEO of Palatin.  “The discussions with EMA have proceeded exceptionally well and we believe their guidance on a phase 3 program and approval pathway has been positive and clear.  We are also in active discussions with multiple pharmaceutical companies on commercialization of bremelanotide in the United States.”

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at http://www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about the prospects of entering into one or more license agreements relating to bremelanotide, potential clinical trial results with bremelanotide, potential actions by regulatory agencies in the United States or Europe relating to bremelanotide, regulatory plans, development programs and the market potential of bremelanotide are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, the ability of Palatin to enter into one or more agreements relating to the commercialization of bremelanotide, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and other regulatory agencies and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

Monday, March 31st, 2014 Uncategorized Comments Off on (PTN) Announces Option Extension for License to Bremelanotide in Europe

(EGLT) Positive Outcome Phase 1 Category 1 Abuse Deterrence Studies for Egalet-001

Study Showed Egalet-001, Extended-Release, Oral Morphine, Resistant to Common Methods of Physical Manipulation

WAYNE, Pa., March 31, 2014  — Egalet Corporation (Nasdaq:EGLT) (“Egalet”) today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet’s proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API).

Egalet is conducting studies to evaluate Egalet-001’s abuse-deterrent properties in accordance with the draft FDA Guidance titled “Abuse-Deterrent Opioids – Evaluation and Labeling.” The first phase of the category 1 in vitro studies tested Egalet-001’s ability to resist a broad range of common methods of physical manipulation, including crushing, cutting or grinding by using readily available items such as spoons, knives or coffee grinders for the purpose of abuse.

The study results demonstrate that Egalet-001 resists the common forms of physical manipulation as compared to MS Contin® (morphine sulfate controlled-release) (“MS Contin”). An independent laboratory tested a number of household tools (electrical and non-electrical) in an effort to reduce the particle size for purposes of abuse. These results confirm tests previously conducted in Egalet’s laboratory that showed Egalet-001’s strong abuse-deterrence features.

“The results from the first phase of our abuse deterrence studies demonstrated that Egalet-001 resists common methods of abuse and manipulation of oral morphine showing an improvement over the treatment options available on the market today,” said Bob Radie, Egalet’s president and chief executive officer. “We are now moving on to the next phase of our abuse deterrence studies and remain optimistic that Egalet-001 will demonstrate its potential as an abuse-deterrent, extended-release oral morphine. This is an important milestone since individuals with moderate to severe chronic pain remain in need of effective medicines that are safe and abuse-deterrent.”

While the first phase of the category 1 abuse deterrence study looked at the ability to physically manipulate Egalet-001, the second phase will test the capacity to extract the active pharmaceutical ingredient (API) from the matrix using common household solvents. Egalet plans to initiate category 2 and 3 abuse deterrence studies for Egalet-001 in the second quarter of 2014. In parallel, Egalet is conducting pivotal bioequivalence studies of Egalet-001 to compare Egalet-001 to MS Contin.

About Egalet-001

Egalet’s lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. There are currently no commercially available abuse-deterrent formulations of morphine, and Egalet-001, if approved, could fill a significant unmet need in the marketplace. The Company developed Egalet-001 using Egalet’s proprietary, abuse-deterrent, one-component delivery system to address common methods of abuse, such as crushing in order to swallow, snort or smoke, or dissolving in order to inject, with an emphasis on the most common method of abuse of morphine-based products, which is abuse by injection. Egalet completed Phase 1 clinical trials of Egalet-001 and recently announced the initiation of pivotal trials to establish the bioequivalence of Egalet-001 to MS Contin, a currently approved oral morphine formulation, in the first quarter of 2014. Egalet plans to submit an NDA for Egalet-001 in the fourth quarter of 2014.

About Egalet Technology

In an effort to address the growing problem of prescription drug abuse, Egalet created two novel, abuse-deterrent technologies with differentiated abuse-deterrent features that allow for the development of oral pharmaceutical products and the ability to control the release profile of the active pharmaceutical ingredient. The Egalet one-component system, which is used for EG-001 our abuse-deterrent morphine program, has been designed to resist common methods of abuse and specifically abuse by injection, the leading method of abuse for morphine. Egalet’s two-component system is used to produce tablets, such as Egalet-002, designed to address common methods of abuse, such as crushing in order to swallow, snort or smoke, or dissolving in order to inject while also offering a greater flexibility and control of API release. In addition, our two-component system offers the ability to develop combination products with the combination of API’s with similar release profiles or different release profiles.

Egalet has employed its proprietary technology platform to develop a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the API.  While Egalet’s lead product candidates are abuse-deterrent, extended-release, oral formulations of commonly prescribed opioids, the Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles.

About Egalet

Egalet Corporation is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications. Egalet has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient. Using its proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation, while also providing tailored release of the active pharmaceutical ingredient. Its lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe chronic pain. There are currently no commercially available abuse-deterrent formulations of morphine, and if approved, Egalet believes that Egalet-001 would fill a significant unmet need in the marketplace. Its second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe chronic pain. The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles. Visit www.egalet.com for more information.

Safe Harbor

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials; our ability to obtain regulatory approval of our product candidates; competitive factors; general market conditions; and other risks factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

CONTACT: E. Blair Clark-Schoeb
         Tel: 917-432-9275
         Email: blair@biotechcomm.com
Monday, March 31st, 2014 Uncategorized Comments Off on (EGLT) Positive Outcome Phase 1 Category 1 Abuse Deterrence Studies for Egalet-001

(MNGA) Signs Joint Venture to Advance Fuel Technologies

MagneGas and FutureEnergy Sign JV to Advance Combustion and Fuel Technologies

TAMPA, Fla., March 31, 2014  — MagneGas Corporation, www.magnegas.com (“MagneGas” or the “Company”) (NASDAQ: MNGA), a leading technology company that counts among its inventions a technology that converts liquid waste into a hydrogen-based fuel, today announced it signed an expanded joint venture agreement with technology partner Future Energy Pty Ltd of Australia.  Under the terms of the agreement, both parties will own 50% of a new Company formed for the purpose of developing, licensing and commercializing new intellectual property for co-combustion of MagneGas fuels with hydrocarbon fuels to reduce emissions and increase energy. This agreement includes and extends beyond the existing partnership of coal co-combustion to include other current and future developments such as the combustion of MagneGas with diesel, heavy oil, aviation fuels, and liquid petroleum gas.

“We believe there are several significant new energy applications by combining MagneGas with existing fuels each with the possibility of reducing emissions and improving combustion efficiency thereby extracting more energy. We are pleased to have expanded our relationship with MagneGas to pursue these confidential opportunities,” commented David Johnston and Lindsay Pukallus, partners of FutureEnergy.

“Future Energy and MagneGas have identified and are already working on several new energy opportunities which leverage the unique properties of MagneGas fuel and the combustion expertise of FutureEnergy. We at MagneGas are pleased to extend our successful relationship and will reveal these new opportunities as they approach certification stage,” stated CEO Ermanno Santilli.

Media interested in learning more and speaking with MagneGas officials either on site or by phone can contact Shelby Malvestuto at 727-934-3448 and shelbymalvestuto@magnegas.com.

About FutureEnergy Pty Ltd

Founded in 2011, the Australian partnership was formed to leverage over 20 years of gas industry and combustion centric experience of the partners.  FutureEnergy has been performing practical and well documented combustion trials with MagneGas and several other hydrocarbon fuels independently and at the request of MagneGas and potential customers.

About MagneGas Corporation

Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is the producer of MagneGas, a natural gas alternative and metal working fuel that can be made from certain industrial, municipal, agricultural and military liquid wastes following the receipt of appropriate governmental permits.

The Company’s patented Plasma Arc Flow process gasifies liquid waste, creating a clean burning hydrogen based fuel that is essentially interchangeable with natural gas. MagneGas can be used for metal working, cooking, heating, powering bi-fuel automobiles and more. For more information on MagneGas, please visit the Company’s website at www.MagneGas.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using new ethylene glycol to produce fuel until proper permits to process used liquid waste have been obtained.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

Monday, March 31st, 2014 Uncategorized Comments Off on (MNGA) Signs Joint Venture to Advance Fuel Technologies

(BLIN) Enters a $7M iAPPSds Licensing Agreement

iAPPSds to Drive 3,700 Independent Physician and Dentist Micro-Websites

BURLINGTON, Mass., March 28, 2014  — Bridgeline Digital, Inc. (Nasdaq:BLIN), The Digital Engagement Company™, a leader in web engagement management, is pleased to announce that it has signed a multi-year, multi-million dollar agreement with a leading healthcare communications technology company in North America. Once deployed, the highly scalable iAPPSds platform will drive 3,700 independent physician and dentist micro-websites. The initial term of this agreement is over 3 years and is valued at approximately $7M in iAPPS licensing fees and related services.

“This customer requires a highly scalable web engagement platform that will allow its vast dealer network to maximize their local digital marketing initiatives and micro-website performance that is core to the iAPPSds web platform,” stated Thomas Massie, Bridgeline Digital’s Chief Executive Officer. “iAPPSds offers state-of-the-art functionality to each local dealer to help them to attract new customers and engage with their local markets. While, at the corporate level, they have complete brand control and the ability to push relevant and consistent content to all 3,700 of their dealers at anytime.”

iAPPSds deeply integrates web content management, eCommerce, eMarketing, Social Media management, and web analytics capabilities into a unified platform. This provides a centralized digital engagement platform for organizations that need to offer their dealer networks access to a high performing local micro-website that they can personalize, use to execute local marketing initiatives, measure results with analytics, and even drive ecommerce initiatives. At a corporate level, iAPPSds provides superior brand control and enables corporate marketing teams the ability to make marketing content available to their dealer network local micro-websites.

About iAPPSds

iAPPSds users have access to premier website features, including the ability to edit and publish forms, images, embedded video, integrated Google Maps, social media plug-ins and other content. Importantly, iAPPSds offers built-in Search Engine Optimization management that includes metadata management, auto-301 redirects, and auto-XML sitemap creation.

iAPPSds is engineered to work with Responsive Design template development, helping ensure that websites are mobile and tablet optimized right out of the box while still leveraging only one single database of content. Furthermore, iAPPSds is able to offer multiple, customized self-service template configurations and styles to end users, enabling them to personalize their site beyond just the content, while still adhering to a company’s brand standards.

iAPPSds is a cloud-based, multi-tenant SaaS solution, that eliminates the need for companies to maintain their own infrastructure for the solution. iAPPSds customers can rely on Bridgeline’s Tier-1, co-location hosting facility whether they are supporting 100, 1,000 or 10,000 franchisee or dealer micro-websites.

About Bridgeline Digital

Bridgeline Digital, The Digital Engagement Company™, enables its customers to maximize the performance of their mission critical websites, micro sites, intranets, and online stores. Bridgeline’s iAPPS® platform deeply integrates Web Content Management, eCommerce, eMarketing, Web Analytics and Social Media management to help marketers deliver online experiences that attract, engage and convert their customers across all digital channels. Bridgeline provides end-to-end Digital Engagement solutions and boasts an award-winning team of interactive services professionals. Headquartered in Burlington, Mass., with ten additional locations throughout North America, Bridgeline has thousands of customers that range from franchises, middle market organizations, to Fortune 1000 companies. To learn more, please visit www.bridgeline.com or call (800) 603-9936.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions, including, but not limited to, the impact of the weakness in the U.S. and international economies on our business, our inability to manage our future growth effectively or profitably, fluctuations in our revenue and quarterly results, our license renewal rate, the impact of competition and our ability to maintain margins or market share, the limited market for our common stock, the volatility of the market price of our common stock, the performance of our products, our ability to respond to rapidly evolving technology and customer requirements, our ability to protect our proprietary technology, the security of our software, our dependence on our management team and key personnel, our ability to hire and retain future key personnel, or our ability to maintain an effective system of internal controls as well as other risks described in our filings with the Securities and Exchange Commission. Any of such risks could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. We expressly disclaim any obligation to update any forward-looking statement.

CONTACT: Bridgeline Digital, Inc.

         Michael Prinn
         Executive Vice President &
         Chief Financial Officer
         781.497.3016
         mprinn@bridgeline.com
Friday, March 28th, 2014 Uncategorized Comments Off on (BLIN) Enters a $7M iAPPSds Licensing Agreement

(IDRA) Announces Positive Top-line Data in Phase 2 Trial of IMO-8400

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. The trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. IMO-8400 treatment met the secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index (PASI). IMO-8400, which is Idera’s lead clinical candidate, is an antagonist of Toll-like receptors (TLRs) 7, 8, and 9. Idera’s strategy is to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.

“Successful completion of this trial is an important additional milestone in our TLR antagonist program. We have studied psoriasis as the initial disease indication to demonstrate clinical proof of concept for our TLR antagonists in autoimmune diseases,” said Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera Pharmaceuticals. “With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need. Towards this goal, our clinical development strategy for IMO-8400 is focused on B-cell lymphomas harboring the MYD88 L265P mutation, and on orphan autoimmune disease indications. Over the remainder of 2014, we anticipate enrolling patients in IMO-8400 trials for Waldenström’s macroglobulinemia, diffuse large B-cell lymphoma and polymyositis and dermatomyositis.”

“We are very pleased to have met the goals of this trial related to safety and tolerability over three months of dosing, and to have obtained evidence of clinical activity with IMO-8400 in psoriasis patients. This provides further validation of the scientific rationale of blocking over-activation of specific TLRs,” commented Lou Brenner, M.D., Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals. “These data also support our clinical development plans for IMO-8400 in genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.”

The trial met its primary objective of demonstrating safety and tolerability at all three dose levels. For all subjects, treatment was well tolerated with no treatment related discontinuation, serious adverse events or dose reductions.

The trial also met a secondary objective of demonstrating clinical activity based on PASI scores. Among patients who completed 12 weeks of treatment per protocol, PASI 50 was achieved in nine (45%) of 20 who received IMO-8400 at any dose level, and in one (14%) of seven who received placebo. PASI 75 was achieved in four (20%) of IMO-8400 treated patients at any dose level, and in zero placebo patients. PASI 50 and PASI 75 are defined as 50% and 75% improvement, respectively, compared to baseline PASI.

About the Phase 2 Trial

This Phase 2 trial is a randomized, double-blind, placebo-controlled trial, in which the Company enrolled 32 patients with moderate-to-severe plaque psoriasis, with a minimum PASI score of 12 or above. All patients were withdrawn from prior therapies with an appropriate wash-out period, and were randomized equally to receive subcutaneous IMO-8400 monotherapy at dose levels of 0.075 mg/kg, 0.15 mg/kg and 0.3 mg/kg or placebo, weekly for 12 weeks, with a six-week follow-up period. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400. A secondary objective of the trial was to evaluate the clinical activity of IMO-8400 as assessed using standard clinical metrics, including Psoriasis Area and Severity Index (PASI) scores.

Additionally, in October 2013, Idera expanded the trial to evaluate a dose of 0.6 mg/kg once weekly and placebo in 12 patients. This trial is being conducted in the Netherlands. Data from this expanded trial are expected to be available by the end of Q2 2014.

Details of the Phase 2 trial of IMO-8400 in psoriasis patients will be submitted for presentation at an upcoming medical meeting.

About Idera’s TLR Antagonist Pipeline

Idera’s TLR antagonist drug candidates have been created using a proprietary chemistry-based drug discovery platform. IMO-8400 is a first-in-class synthetic oligonucleotide-based antagonist of TLRs 7, 8, and 9. IMO-8400 has shown activity in preclinical models of autoimmune diseases, including psoriasis, lupus, and arthritis. IMO-8400 has been well-tolerated in a Phase 1 trial in 42 healthy subjects at single and multiple escalating doses up to 0.6 mg/kg for four weeks, and has shown inhibition of immune responses mediated by TLRs 7, 8, and 9. Idera is pursuing clinical development of IMO-8400 in genetically defined forms of B-cell lymphoma, including Waldenström’s macroglobulinemia and diffuse large B-cell lymphoma, and orphan autoimmune diseases, including polymyositis and dermatomyositis.

The Company has also selected IMO-9200, a second novel antagonist of TLRs 7, 8, and 9, as an additional candidate for potential development in selected autoimmune disease indications. The Company anticipates initiating clinical development of IMO-9200 with the submission of an Investigational New Drug (IND) application in the second half of 2014.

“We are advancing IMO-9200 into clinical development to expand our pipeline of drug candidates with potential use in selected autoimmune disease indications,” added Dr. Agrawal.

About Idera Pharmaceuticals, Inc.

Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). Idera is developing these therapeutics for the treatment of genetically defined forms of B-cell lymphoma and for autoimmune diseases with orphan indications. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company’s strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether results obtained in clinical trials such as the results described in this release will be indicative of the results that will be generated in future clinical trials, including in clinical trials in different disease indications ; whether products based on Idera’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; and such other important factors as are set forth under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Friday, March 28th, 2014 Uncategorized Comments Off on (IDRA) Announces Positive Top-line Data in Phase 2 Trial of IMO-8400

(FFHL) Announces Identity of New Controlling Shareholder

BEIJING, March 28, 2014  –Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL, “Fuwei Films” or the “Company”) announced today that it has learned that Shandong SNTON Optical Materials Technology Co., Ltd. (the “Bidder”) was the successful bidder in the fifth public auction of 6,912,503 shares (or 52.9%) of its outstanding ordinary shares held on March 25, 2014. The winning bid was RMB101,800,000 (approximately US$16,572,787) or approximately US$2.40 per ordinary share. The Company previously announced that it had become aware that the fifth public auction by which the Company’s controlling shareholder, the Weifang State-owned Assets Operation Administration Company, a wholly-owned subsidiary of Weifang State-owned Asset Management and Supervision Committee sought to sell control over, resulted in the acceptance of a successful bid.

According to publicly available information in the People’s Republic of China, the Bidder is an optical BOPET film manufacturer established in August 2011 with registered capital of RMB260 million. The parent company of the Bidder is Shandong SNTON Group Co., Ltd. (the Group), which was founded in January 1987. The Group mainly specializes in metal products, fine chemicals, new materials and real estate development.

About Fuwei Films

Fuwei Films conducts its business through its wholly owned subsidiary, Fuwei Films (Shandong) Co., Ltd. (“Fuwei Shandong”). Fuwei Shandong develops, manufactures and distributes high-quality plastic films using the biaxial oriented stretch technique, otherwise known as BOPET film (biaxially oriented polyethylene terephthalate). Fuwei Films’ BOPET film is widely used to package food, medicine, cosmetics, tobacco, and alcohol, as well as in the imaging, electronics, and magnetic products industries.

Safe Harbor

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to risks. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission which, among other things, include both the short and long-term effects of the global financial crisis on the Company and the BOPET film industry; competition in the BOPET film industry; growth of, and risks inherent in, the BOPET film industry in China; uncertainty as to future profitability and our ability to obtain adequate financing for our planned capital expenditure requirements; uncertainty as to our ability to continuously develop new BOPET film products and keep up with changes in BOPET film technology; risks associated with possible defects and errors in our products; uncertainty as to our ability to protect and enforce our intellectual property rights; uncertainty as to our ability to attract and retain qualified executives and personnel; and uncertainty in acquiring raw materials on time and on acceptable terms, particularly in view of the volatility in the prices of petroleum products in recent years. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of the risk factors.

For more information, please contact:

In China:

Ms Xiaoli Yu
Investor Relations Officer
Phone: +86-133-615-59266
Email: fuweiIR@fuweifilms.com

In the U.S.:

Ms. Vivian Chen
Investor Relations
Grayling
Phone: +1-646-284-9427
Email: vivian.chen@grayling.com

Friday, March 28th, 2014 Uncategorized Comments Off on (FFHL) Announces Identity of New Controlling Shareholder

(ICLD) Refutes Allegations Made Against the Company After Former SEC Prosector’s Investigation

RED BANK, N.J., March 28, 2014  — InterCloud Systems, Inc. (Nasdaq:ICLD) (“InterCloud” or the “Company”) became aware last week of allegations made on a website known as the Southern Investigative Reporting Foundation (“SIRF”) that the Company purportedly paid certain people to write articles and make certain alleged misrepresentations about the Company. InterCloud takes any such allegations seriously and so, in response, the Company hired a former senior federal prosecutor with the United States Securities and Exchange Commission Division of Enforcement and tasked him with conducting an investigation to determine whether there is any truth to these allegations. As a result of this investigation, the Company is now in a position to state that these allegations are wholly without merit. The Rosen Law Firm filed a complaint against the Company based on these reckless allegations. The Company has not been served with any complaint filed at this time. Four other law firms, Bronstein Gewirtz & Grossman, Lifshitz & Miller, Levi & Korsinsky and Rigrodsky & Long, are actively soliciting plaintiffs to join a lawsuit. The Company will vigorously defend itself in any lawsuit filed.

InterCloud CEO Mark Munro stated, “InterCloud has made tremendous strides over the last 18 months. We have grown from little more than $17 million in revenue in 2012, to over $80 million in pro-forma revenues for the twelve months ending September 30, 2013. I take note of the fact that since our public offering on October 31, 2013, every officer and director of our Company has been subject to an underwriter lockup precluding sales of our stock. Nevertheless, because of the seriousness of these allegations, we felt obligated to take the time necessary to investigate whether there was any substance to these claims. We are proud of the accomplishments we have made in offering important cloud solutions to the enterprise and service provider markets. We remain dedicated to completing our mission to make InterCloud one of the foremost cloud and managed service solution providers in the IT services market.”

About InterCloud Systems, Inc.

InterCloud Systems, Inc. is a global single-source provider of value-added IT services for both corporate enterprises and service providers. The company offers cloud and managed services, professional consulting services and voice, data and optical solutions to assist its customers in meeting their changing technology demands. Its engineering, design, installation and maintenance services support the build-out and operation of some of the most advanced enterprise, fiber optic, Ethernet and wireless networks. Additional information regarding InterCloud may be found on the Company’s website at www.intercloudsys.com.

Forward-looking statements:

The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.

CONTACT: Investor Relations
         RedChip Companies, Inc.
         Mike Bowdoin, Vice President
         800-733-2447, ext.110
         Mike@redchip.com
Friday, March 28th, 2014 Uncategorized Comments Off on (ICLD) Refutes Allegations Made Against the Company After Former SEC Prosector’s Investigation

(BIOF) Receives Proposal For A Possible Transaction

DENVER, March 28, 2014  — BIOFUEL ENERGY CORP. (NASDAQ:BIOF) (the “Company”) announced today that it has received a preliminary non-binding proposal (the “Proposal”) from Greenlight Capital, Inc. (together with its affiliates, “Greenlight”) and James R. Brickman (“Brickman” and, together with certain trusts and family members of Brickman, the “Brickman Parties”) for a possible transaction pursuant to which one or more newly-formed, wholly owned subsidiaries of the Company would acquire all of the equity interests of JBGL Capital, LP and JBGL Builder Finance, LLC, and their direct and indirect subsidiaries (collectively, “JBGL”).  JBGL is a series of real estate entities involved in the purchase and development of land for residential purposes, construction lending and home building operations.  JBGL is currently owned and controlled by Greenlight and Brickman.

In response to the Proposal, the board of directors of the Company (the “Board”) will establish a special committee consisting of independent directors to evaluate the Proposal and alternatives for the Company.  The special committee will be authorized to retain independent financial, legal and other advisors.

There can be no assurance that the Proposal or any other transaction will be approved or completed.  No further public disclosure regarding the Proposal is expected to be made until the special committee has completed its deliberations and provided the Board with its recommendation in respect of the Proposal.

This release contains certain forward-looking statements within the meaning of the Federal securities laws.  Such statements are based on management’s current expectations, estimates and projections, which are subject to a wide range of uncertainties and business risks.  Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of whether, or the times by which, our performance or results may be achieved.  Factors that could cause actual results to differ from those anticipated are discussed in our Exchange Act filings and our Annual Report on Form 10-K.

Contact: Kelly G. Maguire For more information:
Executive Vice President & www.bfenergy.com
Chief Financial Officer
(303) 640-6500
kmaguire@bfenergy.com
Friday, March 28th, 2014 Uncategorized Comments Off on (BIOF) Receives Proposal For A Possible Transaction

(SPCB) Selected As The Winning Bidder For Government Contracts Of Over $25M

HERZLIYA, Israel, March 27, 2014  — SuperCom Ltd. (NASDAQ: SPCB), a leading provider of Electronic Intelligence Solutions for National ID, Public Safety and Healthcare, today announced that it has been selected as the winning bidder for contracts amounting to over $25 million. The majority of the revenue from the realization of those contacts will be recognized in 2014.

Commented Arie Trabelsi, President and CEO of SuperCom, “We are very pleased that we are starting to realize the potential of our vast and growing pipeline. These type of contracts, as we have seen in the past, has the potential to lead to long-term relationships and additional orders in future.”

About Supercom
Since 1988, SuperCom has been a leading global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secured Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation.

Company Contact
Ordan Trabelsi, President of US Operations
Tel: 1 212 675 4606
ordan@supercom.com 
Investor Relations Contacts:Ehud Helft & Kenny Green

GK Investor & Public Relations

Tel: 1 646 201 9246

supercom@gkir.com

 

Media Relations Contact:Matthew Krieger

GK Investor & Public Relations

Tel: 1 914 768 4219

matthew@gkipr.com

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded or followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements in this release also include statements about contracts and bid wins, business and economic trends. Investors should also consider the areas of risk described under the heading “Forward Looking Statements” and those factors captioned as “Risk Factors” in the Company’s periodic reports under the Securities Exchange Act of 1934, as amended, or in connection with any forward-looking statements that may be made by the Company. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements arising from the annual audit by management and the Company’s independent auditors. The Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Thursday, March 27th, 2014 Uncategorized Comments Off on (SPCB) Selected As The Winning Bidder For Government Contracts Of Over $25M

(CRRS) Awarded Global Managed Service Provider Agreement with SBM

Corporate Resource Services, Inc. (NASDAQ:CRRS), a diversified technology, staffing, recruiting and consulting services firm, today announced that it has been awarded a three year Managed Service Provider/Vendor Management Services agreement with SBM.

“Corporate Resource Services has been awarded this contract to service SBM in every location they provide their services globally,” said Frank Vaccaro, President of Sales for CRS. “SBM is a global provider of facility services and CRS will be the Managed Service Provider that administers this program throughout all of SBM. The MSP/VMS service offerings create immediate shareholder value and we have other major prospective MSP/VMS agreements pending client approval.”

“This is an example of how a local relationship has catapulted into a global opportunity,” said Roderick Santoro, Regional Vice President of CRS’ West/Central Region. “SBM has been experiencing rapid growth and our diversified service offerings fit perfectly into their staffing strategy both nationally and internationally. During our initial implementation, we have already identified international opportunities that our recent acquisition of Flex Recruitment can fulfill. Our MSP/VMS program will streamline SBM’s staffing process and add value to the overall partnership between CRS and SBM.”

About SBM:

SBM was founded in 1982 in Sacramento, California by Charles Somers (CEO) and Don Tracy (EVP), providing service to the entire Northern California region. With the addition of Ron Alvarado as a partner in 1993, SBM embarked on its national expansion outside of California. Today, SBM employs more than 6,000 individuals servicing more than 350 million square feet throughout the United States, Canada, Singapore and Latin America. SBM’s success has been a direct result of its proven performance, service quality, and cost savings record enabled by industry-leading proprietary technology, which has led to new business opportunities, as well as organic growth among its existing customer base.

SBM provides facility services through a group of affiliated companies, including SBM Site Services, LLC; Somers Building Maintenance Inc.; Pacific West Site Services Inc.; SBM Management Services, LP; SBMSS Site Services Canada Inc.; Interamerican Pacific West Site Services, SA; Pacific West Costa Rica, SRL; and SBM Management Services Puerto Rico LLC.

SBM is proud to be certified by the National Minority Supplier Development Council as a Minority Business Enterprise (MBE). In addition, SBM has attained membership in the National Minority Supplier Development Council (NMSDC) “Corporate Plus” program, demonstrating a proven capability of providing services on a national basis.

SBM offers a full range of building maintenance services including janitorial/housekeeping, vendor management and soft service bundling, using innovative equipment and environmentally minded products, all services are provided by trained and professional staff.

About Corporate Resource Services, Inc.:

Corporate Resource Services, Inc. provides cloud-based enterprise applications and hosting services to PEO and staffing companies, as well as diversified staffing, recruiting, and consulting services. The Company offers trained employees in the areas of Insurance, Information Technology, Accounting, Legal, Engineering, Science, Healthcare, Life Sciences, Creative Services, Hospitality, Retail, General Business and Light Industrial work. The company’s blended staffing solutions are tailored to our customers’ needs and can include customized employee pre-training and testing, on-site facilities management, vendor management, risk assessment and management, market analyses and productivity/occupational engineering studies.

The Company’s ability to deliver broad-based solutions provides its customers a “one stop shop” to fulfill their staffing needs from professional services and consulting to clerical and light industrial positions. Depending on the size and complexity of an assignment, Corporate Resource Services can create an on-site facility for recruiting, training and administration at the customers’ location. Company recruiters have the latest state of the art recruiting resources available to help customers secure the best candidates in today’s ever-changing marketplace. CRS’s national network of recruiters has staffing experts that get excellent results by focusing within their areas of expertise.

The Company operates 244 staffing and on-site facilities throughout the United States and the United Kingdom and it offers its services to a wide variety of clients in many industries, ranging from sole proprietorships to Fortune 1000 companies. To learn more, visit http://www.crsco.com.

This press release contains forward-looking statements, which are subject to risks and uncertainties. Such statements are based on assumptions and expectations which may not be realized and are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, financial and otherwise, may differ from the results discussed in the forward-looking statements. A number of these risks and other factors that might cause differences, some of which could be material, along with additional discussion of forward-looking statements, are set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Thursday, March 27th, 2014 Uncategorized Comments Off on (CRRS) Awarded Global Managed Service Provider Agreement with SBM

(EXAS) Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test.

“We are pleased the Committee strongly supported Cologuard’s approval,” said Kevin T. Conroy, chairman and chief executive of Exact Sciences. “We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening. We thank the FDA and its advisory committee for its careful consideration of Cologuard. We also appreciate the opportunity to participate in the innovative FDA/CMS parallel review program. ”

In the company’s 10,000-patient, 90-site DeeP-C pivotal trial—one of the most extensive colorectal cancer screening studies ever conducted in the United States—Exact Sciences’ Cologuard found 92.3% of colorectal cancer in average risk patients based on a combination of DNA and hemoglobin markers. Exact Sciences submitted the final module of its PMA for Cologuard on June 7, 2013, and the application includes data from that study, which was published online on March 19, 2014, in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3, 2014 print issue.

The FDA is not bound by the recommendation of its advisory committee, but will consider the committee’s guidance as it evaluates the Cologuard PMA.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Thursday, March 27th, 2014 Uncategorized Comments Off on (EXAS) Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard

(CONN) Announces Expansion Of Revolving Credit Facility

Conn’s, Inc. (NASDAQ:CONN), a specialty retailer of home appliances, furniture, mattresses, consumer electronics and provider of consumer credit, today announced that it completed an expansion of its existing asset-based syndicated loan facility that matures November 2017 and that Bank of Texas has joined the facility.

The revolving facility commitment increased $30.0 million to $880.0 million with the additional financial partner and increased commitment levels within the existing syndicate of banks.

The lenders in the syndicated facility include 17 commercial banks: Bank of America, N.A.; JPMorgan Chase Bank, N.A.; Regions Bank; Union Bank, N.A.; Capital One, N.A.; Compass Bank; Amegy Bank; First Tennessee Bank National Association; City National Bank; Synovus Bank; Whitney Bank; Amalgamated Bank; BOKF, NA DBA Bank of Texas; Cole Taylor Bank; Cathay Bank; Israel Discount Bank of New York and Green Bank, N.A. The syndication was arranged through Bank of America, N.A.

About Conn’s, Inc.

Conn’s is a specialty retailer operating more than 75 retail locations in Texas, Louisiana, Arizona, Oklahoma and New Mexico. The company’s primary product categories include:

  • Home appliance, including refrigerators, freezers, washers, dryers, dishwashers and ranges;
  • Furniture and mattress, including furniture and related accessories for the living room, dining room and bedroom, as well as both traditional and specialty mattresses;
  • Consumer electronic, including LCD, LED, 3-D, Ultra HD and plasma televisions, Blu-ray players, home theater and video game products, digital cameras, and portable audio equipment; and
  • Home office, including computers, tablets, printers and accessories.

Additionally, Conn’s offers a variety of products on a seasonal basis. Unlike many of its competitors, the company provides flexible in-house credit options for its customers in addition to third-party financing programs and third-party rent-to-own payment plans.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include information concerning our future financial performance, business strategy, plans, goals and objectives. Statements containing the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” or the negative of such terms or other similar expressions are generally forward-looking in nature and not historical facts. Although we believe that the expectations, opinions, projections, and comments reflected in these forward-looking statements are reasonable, we can give no assurance that such statements will prove to be correct. A wide variety of potential risks, uncertainties, and other factors could materially affect our ability to achieve the results either expressed or implied by our forward-looking statements including, but not limited to: general economic conditions impacting our customers or potential customers; our ability to continue existing or offer new customer financing programs; changes in the delinquency status of our credit portfolio; increased regulatory oversight; higher than anticipated net charge-offs in the credit portfolio; the success of our planned opening of new stores and the updating of existing stores; technological and market developments and sales trends for our major product offerings; our ability to protect against cyberattacks or data security breaches and protect the integrity and security of individually identifiable data of our customers and our employees, our ability to fund our operations, capital expenditures, debt repayment and expansion from cash flows from operations, borrowings from our revolving credit facility, and proceeds from accessing debt or equity markets; and the other risks detailed in our SEC reports, including but not limited to, our Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, we are not obligated to publicly release any revisions or update to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Thursday, March 27th, 2014 Uncategorized Comments Off on (CONN) Announces Expansion Of Revolving Credit Facility

(NWBO) To Present At The 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference

BETHESDA, Md., March 27, 2014  — Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an overview of the Company’s DCVax® cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct.

There will be a live audio webcast of this presentation at: http://nwbio.com/webcasts/

About the 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference: Hosted by Maidstone Life Sciences LLC, the 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” conference event unites key opinion leaders in Immuno-oncology, Wall Street research analysts, venture capitalists, institutional investors, media, and company executives to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of Immuno-oncology.

About Northwest Biotherapeutics

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company’s lead product, DCVax-L, is currently in a 312-patient Phase III trial in the U.S. and Europe for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.  The Company has also conducted a small Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patient s in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings.  Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Thursday, March 27th, 2014 Uncategorized Comments Off on (NWBO) To Present At The 4th Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference

(PESI) Validation of Medical Isotope Technology

New Process to Produce Technetium-99m Eliminates the Need for Both High and Low Enriched Uranium Targets

ATLANTA, GA–(March 27, 2014) – Perma-Fix Medical Corporation, a wholly owned subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) today announced successful validation of its process to produce Technetium-99m (Tc-99m) from Molybdenum-99 (Mo-99) using standard reactors at two of the premier research institutions in Poland and the United States. The first set of tests were conducted at POLATOM in Warsaw, Poland and reaffirmed previous testing that the Company’s proprietary resins could withstand high levels of radiation, while meeting regulatory standards for the production of Tc-99m. The second set of tests, conducted at the Missouri University Research Reactor (MURR) in Columbia, Missouri, reinforced the POLATOM results and demonstrated higher elution efficiencies. We have filed patent applications in connection with our new process to produce Tc-99m from Mo-99.

Dr. Louis F. Centofanti, CEO of Perma-Fix Medical and Perma-Fix Environmental Services, commented, “These results further validate the strength of our technology, which we believe has the potential to reshape the global supply chain of Tc-99m in the United States and around the world. We believe the new process is a less expensive process and does not require the use of government-subsidized, weapons-grade materials. We believe our process also addresses important issues associated with current production methods. Our process can be performed in most standard research reactors, which should help solve concerns regarding supply shortages of Tc-99m around the world. Second, our process does not utilize Highly Enriched Uranium (HEU) or Low Enriched Uranium (LEU) targets, which are frequently cited as proliferation risks. Lastly, we believe our process eliminates many environmental concerns associated with the current Mo-99 production methodology, including issues around reprocessing of target materials and production of high level waste requiring permanent disposal not currently provided for.”

By way of background, Tc-99m is the most widely used medical isotope in the world. It allows medical practitioners to image internal body organs and is used in 80-85% of the 25 million diagnostic nuclear medical procedures each year in the U.S. alone. Common procedures include: cardiac imaging; cancer detection bone scans; gastrointestinal issues; and imaging of the brain, kidney, spleen and infections. The radioisotope market in Europe alone is expected to reach $1.6 billion in 2017, up from $1.1 billion in 2012.

Nearly all of the world’s supply of Tc-99m comes from the thermal fission of highly enriched uranium (HEU) targets in a small number of highly specialized reactors. The current process is costly and has proven an unreliable source of radioactive material leading to severe worldwide shortages. The scheduled closure of the NRU reactor in 2016 and the OSIRIS reactor in France in 2018 are expected to have a further impact on the manufacturing and supply of these isotopes. The current process also raises serious proliferation concerns related to the threat associated with international production, transportation and/or use of HEU in the production of medical isotopes.

We believe that Perma-Fix’s technology overcomes these issues by using neutron capture to activate natural Molybdenum, a common metal, to produce Mo-99, which decays into Tc-99m. Unlike conventional processes, the Perma-Fix Medical process can be produced locally using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. The new process encompasses the full production cycle, from reactor to final medical supply, and should be easily deployable around the world.

To overcome past issues with neutron activation of Molybdenum, Perma-Fix has developed a specialized resin that is radiation resistant and holds large quantities of Molybdenum, but at the same time releases almost 90% of the Tc-99m as it forms from the decay of Mo-99. The resin, loaded with the activated Mo-99, is placed in a Technetium generator and slowly washed with a saline based solution. The eluent solution containing Tc-99m has been shown to meet targeted USP and EUP standards for Pertechnetate.

About Perma-Fix Medical
Perma-Fix Medical with headquarters in Atlanta, Georgia (USA), is a subsidiary of Perma-Fix Environmental Services, a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company’s nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the Department of Defense (“DOD”), and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities. Please visit us on the World Wide Web at http://www.perma-fix.com.

This press release contains “forward-looking statements” which are based largely on the Company’s expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company’s control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, but are not limited to: less expensive process, our process could help solve concerns regarding supply shortage of Tc-99, and elimination of many environmental concerns associated with current Mo-99 manufacturing methods. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; industry conditions; competitive pressures; our ability to produce and market our new technology; U.S. and foreign governmental laws and regulations adopted from time to time; inability to raise necessary capital for Perma-Fix Medical; validity of our patents or patent applications in connection with this new technology; and the additional factors referred to under “Special Note Regarding Forward-Looking Statements” of our 2012 Form 10-K/A and continued in our March 31, June 30 and September 30, 2013 Form 10-Qs. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

Please visit us on the World Wide Web at http://www.perma-fix.com.

Contacts:
David K. Waldman-US Investor Relations
Crescendo Communications, LLC
(212) 671-1021

Herbert Strauss-European Investor Relations
herbert@eu-ir.com
+43 316 296 316

Thursday, March 27th, 2014 Uncategorized Comments Off on (PESI) Validation of Medical Isotope Technology

(CPXX) Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic and AML

EWING, N.J., March 26, 2014  — Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.

“Disease progression after hypomethylating agent treatment in patients with MDS and AML signals poor prognosis. As a consequence, Celator is extending the use of CPX-351 as a potential treatment for patients no longer responsive to HMA therapy in a clinical trial that will be led by investigator Bruno C. Medeiros at the Stanford University School of Medicine,” said Arthur C. Louie, Chief Medical Officer of Celator Pharmaceuticals. “We are delighted to support proposals from investigators for studying indications beyond secondary AML.”

The Phase 2 study is expected to enroll up to 33 patients, with the primary objective being to determine the efficacy and safety profile of CPX-351 in patients 60 years of age and older with higher risk MDS or AML. Patients must have progressed after prior HMA therapy. This includes patients older than 75 years of age with higher risk MDS who are HMA relapsed/refractory who have progressed to AML, as well as AML patients with relapsed/refractory disease after prior HMA therapy for AML. Patients will receive a first induction of CPX-351 on days 1, 3, and 5 and, if a morphological leukemia-free state is not achieved, they will receive a second course of induction therapy. After one or two inductions, patients achieving complete remission (with or without blood count recovery) will receive consolidation therapy with CPX-351 on days 1 and 3.

Secondary endpoints include the duration of remission, overall survival at 12 months and early mortality within 60 days of first induction.

“We continue to be excited by the interest from investigators in evaluating CPX-351 in broader patient populations,” said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals. “We believe there is significant potential for CPX-351 as a treatment for other hematologic malignancies beyond secondary AML, the indication being studied in the ongoing Phase 3 study, and remain committed to exploring this further.”

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:cisplatin), and the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. For more information, please visit the company’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements 

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the potential efficacy and therapeutic potential of CPX-351, whether clinical results for CPX-351 obtained to date will be predictive of future clinical study results, and our expectations regarding our development plans for CPX-351 and our drug candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator’s Form 10-K for the year ended December 31, 2013 and other filings by the company with the U.S. Securities and Exchange Commission.

CONTACT: Media:
         Sam Brown, Inc.
         Mike Beyer, 773-463-4211
         beyer@sambrown.com
         or
         Investors:
         Stern Investor Relations, Inc.
         Beth DelGiacco, 212-362-1200
         beth@sternir.com
Wednesday, March 26th, 2014 Uncategorized Comments Off on (CPXX) Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic and AML

(LGL) $3B Aero/Defense Client Sharpens Focus with MtronPTI

MtronPTI, leader in precision frequency control and custom RF/microwave filters, today announced the SA0068 30 Watt 7-way Switched Filter Bank for multiband radio applications. Paul Dechen, Vice President of Sales for MtronPTI, says, “Moving faster and focusing on core skills is how communications system makers win in this competitive environment. When this new client learned about MtronPTI’s capabilities, they asked us to take on part of a new system project. The result is the SA0068 Switched Filter module and better use of the client’s engineering resources.”

Defense and commercial end users alike want to see complete systems functioning before placing the order. Gone are the days of building to contract with only a promise of delivery. To anticipate client needs in advance, design and build the product before the competition, system makers must focus on what they do best and outsource the RF signal portion to companies like MtronPTI, who are specialists at that technology.

Paul continues, “This $3 billion electronics system company needed to make performance and power improvements in a portable multi-band radio application. By partnering with MtronPTI, our years of RF design and precision filter production expertise brings the Client’s new radio higher performance RF with lower production risks. Now their engineers are free to focus more on overall system design.”

According to Strategic Analytics†, the market for communications capabilities across land, air, naval and space domains is approaching $29 billion. Land-based tactical radios are expected to grow at a compound annual growth rate (CAGR) of 7.2% to about $4.5 billion by 2022. Within the radio universe, multi-band radios will be the fastest growth segment with electronic component market predicted to grow at almost 14% CAGR to $721 million in 2022.

MtronPTI’s SA0068 7-way Switched Filter Bank provides transmitter harmonic management with at least 30 dB of 2nd harmonic rejection in seven selectable frequency bands from 30 MHz to 512 MHz. With a low insertion loss of less than 1.3 dB, 30 Watts of power handling and a small, 65 mA current drain max, the SA0068 is ideal for applications such as multiband tactical radios and portable radio power amplifiers.

About MtronPTI

MtronPTI is an AS9100 rev C certified designer and manufacturer of advanced highly engineered frequency control and filter products for aerospace, defense, instrumentation and Internet communication applications. Based in Orlando, Florida, with design, sales and manufacturing locations in North America, Asia and Europe, MtronPTI is a subsidiary of The LGL Group (NYSE MKT: LGL). For more information, visit http://www.mtronpti.com and http://www.lglgroup.com.

Wednesday, March 26th, 2014 Uncategorized Comments Off on (LGL) $3B Aero/Defense Client Sharpens Focus with MtronPTI

(CREG) New USD 32.6m CDQ Project with Estimated Annual Net Profit of USD 7.63m

XI’AN, China, March 26, 2014  — China Recycling Energy Corp. (NASDAQ: CREG; “CREG” or “the Company”), a leading industrial waste-to-energy solution provider in China, today announced that its subsidiary Xi’an TCH Energy Technology Co., Ltd (“Xi’an TCH” or “the Company”) has signed an EMC Contract with Tangshan Baoliyuan Coking Co., Ltd. (“Baoliyuan”), to invest a Coke Dry Quenching (CDQ) waste heat power generation project using BOT method.

Baoliyuan is a steel company which mainly engages in coking and rolled steel with an annual production capacity of 1.1 million ton. Xi’an TCH will construct a coke dry quenching (CDQ) system and a 25MW waste heat power generation plant based on Baoliyuan’s existing industrial flow. The company will recycle the waste heat during manufacturing process to generate electricity while reducing emissions. The generated electricity will be purchased by Baoliyuan and Xi’an TCH will charge an energy saving service fee based on generated electricity.

The purpose of this contract is to invest USD 32.6 million to build an ancillary CDQ facility and waste heat power plant. Xi’an TCH will provide funds, construction, equipment procurement, operation and management for the power generation project. The operation term is 20 years. Baoliyuan shall pay energy an saving service fee at $0.114 per kilowatt hour for the power generated from the system during the operation term. The estimated annual net income will be USD 7.63 million and the payback period is 4 years.

Mr. Guohua Ku, Chairman and CEO of CREG commented, “We are very pleased with the signing of this contract. Coke Dry Quenching waste heat power generation is a revolutionary technology in the coke industry. It can reuse the waste heat while reducing emissions at the same time. The Chinese government gives strong support to environmentally-friendly technology. It is the future trend that Coke Dry Quenching will substitute the wet quenching technique. This project can expand our project portfolio, bring more profit and make a greater contribute to our environment.”

About China Recycling Energy Corp.

China Recycling Energy Corp. (NASDAQ: CREG or “the Company”) is a leading developer of waste energy recycling projects for industrial applications in China. Our waste energy recycling projects allow customers who use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. We currently offer waste energy recycling systems to companies for use in iron and steel, nonferrous metal, cement, coal and petrochemical plants. We construct our projects at our customer’s facility and the electricity produced is used on-site by the customer. We provide an energy-efficient solution aimed at reducing the emission and air pollution in China. Our recycling energy projects capture industrial waste energy to produce low-cost electricity, enabling industrial manufacturers to reduce their energy costs, lower their operating costs and extend the life of primary manufacturing equipment. The Chinese government has adopted policies to encourage the use of recycling technologies to optimize resource allocation and reduce pollution. Currently, recycled energy represents only an estimated 1 percent of total energy consumption and this renewable energy resource is viewed as a growth market due to intensified environmental concerns and rising energy costs as the Chinese economy continues to expand. Our management and engineering teams have over 20 years of experience in industrial energy recovery in China. For more information about CREG, please visit http://www.creg-cn.com.

About Tangshan Baoliyuan Coking Co., Ltd.

Tangshan Baoliyuan Coking Co., Ltd. was founded in 2003 and located in Shaheyi Town, Qian’an City, covering an area of 300 mu, with 820 employees and annual production capacity is 1.1 million tons of coke. They have 5.5 meters coke oven, coke quenching, coal preparing, screening and cooling coke, desulfurization, thiamine, elution benzene and utilities and auxiliary project of the accessory factory, amongst which, part of indicators have reached international level of coke standard. They have their own special railway and warehousing and logistic center. Its geographical location is very convenient for water and land transportation.

Safe Harbor Statement

This press release may contain certain “forward-looking statements” relating to the business of China Recycling Energy Corp. and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Mr. David Chong
Chief Financial Officer
China Recycling Energy Corp.
Tel: +86-13701813139
+65-9721 6163
Email: chongscd@creg-cn.com

Wednesday, March 26th, 2014 Uncategorized Comments Off on (CREG) New USD 32.6m CDQ Project with Estimated Annual Net Profit of USD 7.63m

(RENT) Expands Contract With Rentrak Local TV Service For Entire TV Station Group

–Bonten Media Goes All-in with Rentrak by Adding Local TV Ratings Across Its 13 Television Stations in Eight Markets–

PORTLAND, Ore., March 26, 2014  — Rentrak (NASDAQ: RENT), the leader in precisely measuring movies and TV everywhere, today announced a long-term, group-wide, local TV ratings expansion with Bonten Media across their 13 stations in eight markets.

“We started working with Rentrak a few years ago in Tri-Cities, TN/VA and have learned to appreciate the quality of 365-day-a-year measurement and the immediacy of the information. So, it was a natural progression to expand our partnership across the entire group,” said Randall D. (Randy) Bongarten, chairman and chief executive officer of Bonten Media. “Rentrak has created a robustly competitive TV measurement marketplace based on millions of homes across the country, which Bonten and the industry stand to benefit significantly from. They provide stable and reliable ratings and audience insights that we can use with our agency and advertiser partners and to make news and programing decisions.”

“Bonten Media’s philosophy of creating a culture of excellence has made them a very well-respected broadcaster,” said Rentrak’s Executive Vice President, Local Market Television, Steve Walsh.  “We are most happy to expand our partnership with them and continue growing our transactional adoption across the industry. We look forward to working closely with them and providing them with audience information that allows them to sell, not only the size of their audiences, but on their value, benefiting both them and their clients.”

About Rentrak
Rentrak (NASDAQ: RENT) is the entertainment and marketing industries’ premier provider of worldwide consumer viewership information, precisely measuring actual viewing behavior of movies and TV everywhere. Using our proprietary intelligence and technology, combined with Advanced Demographics, only Rentrak is the census currency for VOD and movies. Rentrak provides the stable and robust audience measurement services that movie, television and advertising professionals across the globe have come to rely on to better deliver their business goals and more precisely target advertising across numerous platforms including box office, multiscreen television and home video. For more information on Rentrak, please visit www.rentrak.com.

RENTM

Contact for Rentrak:
Antoine Ibrahim
Office: 646-722-1561
E-mail: aibrahim@rentrak.com

Wednesday, March 26th, 2014 Uncategorized Comments Off on (RENT) Expands Contract With Rentrak Local TV Service For Entire TV Station Group

(INVE) Jason Hart to Participate in Thought Leaders Panel Discussion on Internet of Things

FREMONT, Calif., March 26, 2014  — Identiv (Nasdaq:INVE) today announced that its CEO, Jason Hart, will participate in a thought leaders panel discussion at Mountain Partners’ EntrepreneursDay 2014 in Lake Tegernsee, Germany.

More than 350 selected executives, entrepreneurs and investors will take part in this two-day event on March 27 and 28, 2014 to explore the future of the Internet as one of the drivers of economic growth. This year’s event seeks to answer the questions of whom could the “digital revolution” be an opportunity for success, which business models are really sustainable and is it possible to combine security and data protection with the digital revolution?

“The emerging market of delivering trust to the Internet of Things will continue to become more crucial as the growing number of everyday items are subjected to the duality of the physical and digital worlds,” said Jason Hart, CEO of Identiv. “Everything is being connected. We at Identiv are building a trust platform that is sustainable for the future of the digital revolution. I’m looking forward to participating in Friday’s panel and sharing our vision of trust in the connected world.”

Jason Hart will speak during the “Dragon’s Den” panel, hosted by Nicolas Gabrysch and Osborne Clarke, on Friday, March 28, 2014. Find out more about EntrepreneursDay 2014 at www.unternehmertag2014.com.

About Identiv

Identiv is a global security technology company that establishes trust in the connected world, including premises, information and everyday items. CIOs, CSOs and product departments rely upon Identiv’s trust solutions to reduce risk, achieve compliance and protect brand identity. Identiv’s trust solutions are implemented using standards-driven products and technology, such as digital certificates, mobility and cloud services. For more information, visit www.identiv.com.

CONTACT: Identiv Media Contacts:
         Lesley Sullivan/Joann Wardrip
         MSLGROUP
         781-684-0770
         IdentivGroup@mslgroup.com
Wednesday, March 26th, 2014 Uncategorized Comments Off on (INVE) Jason Hart to Participate in Thought Leaders Panel Discussion on Internet of Things

(ETAK) Appoints Carl D. Stevens and Geoffrey Leland to its Board of Directors

New Independent Board Members Bring Additional Telecommunications, Management and Capital Markets Expertise to Elephant Talk Board

OKLAHOMA CITY, March 26, 2014 — Elephant Talk Communications Corp. (NYSE MKT: ETAK) (“Elephant Talk” or the “Company”), a global provider of Software Defined Network Architecture (Software DNA™ 2.0) platforms and cyber security solutions, today announced the appointment of two independent Directors to the Company’s Board of Directors (the “Board”). Effective April 1, 2014, Carl D. Stevens and Geoffrey Leland will join the Board, filling vacancies created following the 2013 annual meeting of stockholders in December 2013.

As part of their appointment, Mr. Stevens and Mr. Leland will join Mr. Rijkman Groenink as members of the Board’s Audit and Finance Committee, the Compensation Committee and the Nominating and Corporate Governance Committee.

Mr. Steven van der Velden, Chairman and CEO stated: “Elephant Talk is very proud to welcome Carl and Geoffrey as independent members to its Board. Their collective wealth of knowledge and relevant industry expertise will be of great value to our Company and our stockholders as we continue to execute on our long-term growth plans.”

Geoffrey Leland, 44, is the Founder and Principal of LTR Advisory Limited, a Technology, Media and Telecommunications focused advisory firm. Previously, Mr. Leland served in a number of roles on the technology and telecoms team at Apax Partners SA. His capital market experience includes serving as a Senior Associate at Cowen’s London-based Technology Corporate Finance division and in the Mergers and Acquisitions Division at BNP Paribas. He has also served as a director for a number of technology companies including Vizada, Odyssey Financial Technologies and Aims Software, as well as board observer of Cartesis, CCMX, DxO Labs, and Avisium. Mr. Leland received an M.B.A., with distinction (Beta Gamma Sigma) from UC Berkeley’s Haas School and an undergraduate Bachelor’s degree from the University of Pennsylvania.

Carl D. Stevens, 67, brings to Elephant Talk significant senior-level management experience including 26 years at IBM where he held various sales and management positions including founding and managing IBM’s National Distribution Division’s Contract Compliance Department. Previously, Mr. Stevens served as CEO and President of Cogient Corporation, a medical software and services provider. Earlier, he held the position of Division President at Infocast Corporation Inc. where he headed the Company’s e-Learning and Virtual Contact Center divisions and had served as President and CEO of ITC Corp., a NASDAQ-listed publisher and distributor of multimedia training materials. Mr. Stevens served as a member of the compensation committee of the board of directors of Diamondhead Casino Corporation. He attended Indiana University where he majored in business administration. Mr. Stevens is a veteran of the United States Air Force.

About Elephant Talk Communications Corp.:

Elephant Talk Communications Corp. (NYSE MKT: ETAK), is a global provider of mobile proprietary Software Defined Network Architecture (Software DNA™ 2.0) platforms for the telecommunications industry. The Company empowers Mobile Network Operators (MNOs), Mobile Virtual Network Operators (MVNOs), Enablers (MVNEs) and Aggregators (MVNAs) with a full suite of applications, superior Industry Expertise and high quality Customer Service without substantial upfront investment. Elephant Talk counts several of the world’s leading Mobile Network Operators amongst its customers, including Vodafone, T-Mobile, Zain and Iusacell. Visit: www.elephanttalk.com.

About ValidSoft UK Limited:

ValidSoft UK Limited (“ValidSoft”) provides advanced mobile-and cloud-security solutions. ValidSoft’s custom-built sophisticated multi-factor authentication platform (SMART™) takes full advantage of telecommunications and includes a leading proprietary voice biometric engine. The platform combats electronic fraud and safeguards consumer privacy across internet, mobile banking, card, mobile and fixed line telecommunication channels. The company counts some of the largest financial institutions among its customers. ValidSoft is the only security software company in the world that has been granted three European Privacy Seals. Visit: www.validsoft.com.

Forward-Looking Statements
Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to Elephant Talk’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about Elephant Talk’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict, including, without limitation, the ability of the Company to regain compliance with the listing standards of the NYSE MKT. Because such statements involve risks and uncertainties, the actual results and performance of Elephant Talk may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, Elephant Talk also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from those projected or suggested  in Elephant Talk’s filings with the Securities and Exchange Commission (the “SEC”), copies of which are available from the SEC or may be obtained upon request from Elephant Talk.

Contacts:

Investor Relations:
Steve Gersten
Elephant Talk Communications Corp.
+ 1 813 926 8920
steve.gersten@elephanttalk.com

Thomas Walsh
Alliance Advisors
+ 1 212 398 3486
twalsh@allianceadvisors.net

Public Relations:
US: Michael Glickman
MWG CO
(917) 596.1883
mike@mwgco.net

Wednesday, March 26th, 2014 Uncategorized Comments Off on (ETAK) Appoints Carl D. Stevens and Geoffrey Leland to its Board of Directors

(NPSP) Expands Executive Leadership Team to Support Growth

– Paul Firuta named President, U.S. Commercial Operations – Eric Pauwels promoted to President, NPS Pharma International

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced the appointment and promotion of two key executives to support the company’s vision of becoming the world’s premier orphan drug business.

Paul Firuta has joined NPS as president, U.S. commercial operations. Most recently, Mr. Firuta was vice president and general manager, Americas for ViroPharma, Inc. While at ViroPharma, Mr. Firuta led the U.S. launch of the orphan biologic product, Cinryze®, a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema, or HAE. Cinryze was launched in December 2008 and generated $97 million in first-year sales, making it one of the most successful orphan drug launches in the U.S. Prior to ViroPharma, Mr. Firuta held commercial leadership positions at OraPharma, Inc. and SmithKline Beecham Pharmaceuticals (GlaxoSmithKline).

To support NPS’ continued expansion into international markets, Eric Pauwels has been promoted to the new position of president, NPS Pharma International and will be responsible for all international commercial operations. Since joining NPS in September 2011, Mr. Pauwels has built a high-caliber commercial team and directed the successful U.S. launch of Gattex® (teduglutide [rDNA origin]) for injection for adult Short Bowel Syndrome, or SBS. Before joining NPS, Mr. Pauwels led the worldwide commercial functions for the Human Genetic Therapies (HGT) division of Shire plc.

“I am delighted that Paul Firuta will be leading our U.S. Commercial Operations and serve as the U.S. counterpart to Eric Pauwels who will now devote his skills and talents to building our international capabilities. The expansion of our leadership team and focus will help us accelerate our global growth strategy to build the world’s premier rare disease company,” said Francois Nader, MD, president and chief executive officer, NPS Pharmaceuticals. “Paul’s successful track record makes him the ideal executive to deliver continued success for Gattex® while preparing for the launch of Natpara®. And Eric’s extensive experience building international commercial teams, along with his deep global understanding of the orphan drug landscape, makes him ideally suited to run our international commercial operations.”

About NPS Pharmaceuticals

NPS Pharmaceuticals is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The company’s lead product, Gattex® (teduglutide [rDNA origin]) for injection is approved in the US for adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. In the EU, teduglutide (trade name: Revestive®) is approved for the treatment of adult patients with SBS; patients should be stable following a period of intestinal adaptation after surgery. Teduglutide is not approved for the treatment of pediatric SBS patients. The safety and efficacy of teduglutide in this population is currently being evaluated in a global registration trial.

A Biologics License Application is undergoing FDA review for Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone. The Prescription Drug User Fee Act goal date for the Natpara application is October 24, 2014.

NPS’ earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium sensing receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.

Additional information about NPS is available through its corporate website, http://www.npsp.com.

“NPS,” “NPS Pharmaceuticals,” “Gattex,” “Natpara,” “Preotact,” and “Revestive” are the company’s trademarks.

Disclosure notice

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward looking statements include, but are not limited to, statements concerning the company’s future financial performance and plans for the commercialization of its products, beliefs or expectations regarding our products in development, statements concerning the company’s plans for international expansion, beliefs or expectations regarding potential revenue and earnings from product sales, including beliefs regarding our ability to grow sales, expectations regarding the market size for our products, including those in development, and beliefs or expectations regarding our operating expenses. Risks associated to the company’s business include, but are not limited to, the risks associated with any failure by the company to successfully commercialize Gattex/Revestive (teduglutide [rDNA origin]) for injection, including the risk that physicians and patients may not see the advantages of Gattex/Revestive and may therefore be reluctant to utilize the product, the risk that private and public payers may be reluctant to cover or provide reimbursement for Gattex, risks related to regulatory approvals for Natpara (recombinant human parathyroid hormone 1-84 (rhPTH 1-84)), the risks associated with the company’s strategy, global macroeconomic conditions, the impact of changes in management or staff levels, the effect of legislation effecting healthcare reform in the United States, as well as other risk factors described in the company’s periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this press release and NPS undertakes no duty to update this information, whether as a result of new information, future events or otherwise.

Tuesday, March 25th, 2014 Uncategorized Comments Off on (NPSP) Expands Executive Leadership Team to Support Growth

(IMMY) Scheduled to Present at 13th Annual Needham Healthcare Conference

SAN DIEGO, March 25, 2014  — Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.

Mr. Baum will be available for one-on-one meetings for conference attendees through the conference request process. Any other meeting requests outside of this event can be directed to the Imprimis IR Team at ir@imprimispharma.com. The April 9th presentation will be webcast and can be accessed on the “Events” page of the Company’s website at www.imprimispharma.com.

ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis’ patent-pending technologies and formulations are available today and are being prescribed by physicians.  For more information, please visit  or www.GoDropless.com.

SAFE HARBOR
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis’ ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis’ ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll
jcarroll@imprimispharma.com
858.704.4587

Tuesday, March 25th, 2014 Uncategorized Comments Off on (IMMY) Scheduled to Present at 13th Annual Needham Healthcare Conference

(DBLE) Petroleum Appoints Charles F. Chambers CEO

DENVER, March 25, 2014  — Double Eagle Petroleum Co. (the “Company”) (NASDAQ:  DBLE) announced today that Charles F. Chambers has been appointed Chairman and Chief Executive Officer, effective as of April 1, 2014, succeeding Richard D. Dole who will become Vice Chairman of the Board.  As part of the transition the Company is changing its name to Escalera Resources Co.  The Company also announced a private placement of its common stock for $4,825,000, the net proceeds of which will be used to fund working capital needs and for other general corporate purposes.

New Chief Executive Officer

Mr. Chambers has spent 40 years in the upstream oil and gas business.  From March 2012 to November 2013, he was the Managing Director of Castleton Commodities International LLC’s Oil & Gas Business, responsible for managing upstream business activities with a focus on building a domestic natural gas portfolio.  From 2005 to 2008, Mr. Chambers held various positions at Rosetta Resources Inc., including Chief Executive Officer.  Prior to Rosetta Resources Inc., Mr. Chambers served as Executive Vice President of Calpine Corporation and managed its acquisition efforts.  Prior to joining Calpine, Mr. Chambers held positions at C&K Petroleum, Chambers Oil & Gas, Sheridan Energy and Grand Gulf Production. In addition to serving as Chief Executive Officer, Mr. Chambers will also serve as Chairman of the Company’s Board of Directors.

The search for a new Chief Executive Officer was led by Mr. Dole on behalf of the Board and was focused on finding deep industry expertise to focus on new project generation and gaining greater access to industry talent and capital markets.  “Mr. Chambers brings significant experience in the energy industry to Double Eagle and superb deal-making experience and skills,” Mr. Dole said.

“I found Double Eagle to be a perfect platform to bolt on new opportunities for substantial growth. We are already in discussions with several top industry players to join the company and support our growth and are already focusing on several potential new projects,” Mr. Chambers said.

Mr. Dole has agreed to work with the Company on transition activities and new project development. Mr. Dole will become Vice Chairman of the Board, will be a consultant to the Company and will assist the Chief Executive Officer on transition matters and the Company’s acquisition activities.

Appointment of President for Company’s New Subsidiary Escalera International Co. LLC

Dr. Erkan (Eric) Icsel has been appointed President of Escalera International Co. LLC, effective as of April 1, 2014, to focus on upstream and midstream international opportunities, first in Central Asia and later in Africa.

Dr. Icsel is a seasoned energy and international business executive with over 41 years of development experience in international energy projects.  He has successfully negotiated contracts, concessions, and corporate privileges at the highest levels of government and industry in countries such as Turkey, Russia, Kazakhstan, Azerbaijan, Kyrgyzstan, and several African nations.

Mr. Chambers, Mr. Dole and Dr. Icsel will office in Houston, and the Company’s finance, administration and Rocky Mountain operations will remain in Denver.

Company to Change Name to Escalera Resources Co.

In connection with Mr. Chambers’ appointment as Chief Executive Officer, the Company is changing its name to Escalera Resources Co.  The new trading symbol for its common stock will be ESCR, and the Company’s preferred stock will trade under the symbol ESCRP.  The Company’s new website is being constructed.  The Board of Directors felt the name change was an essential step in the repositioning of the Company for future growth as we look to expand beyond our traditional role of onshore, domestic natural gas. This name change will be effective April 1, 2014.

Sale of Common Stock

The Company issued a total of approximately 2,019,000 shares of common stock at a price of $2.39 per share for total gross proceeds of $4,825,000.  The offering was effected through a private placement transaction with primarily individual investors.  The net proceeds of the private offering will be used to fund working capital needs, capital expenditures, acquisitions of interests in oil and natural gas assets, and for general corporate purposes.  Petrie Partners Securities, LLC served as placement agent for the Company.

About Escalera Resources Co./Double Eagle Petroleum Co.

Escalera Resources Co. will have offices in Houston, Texas, Denver, Colorado and Casper, Wyoming. The Company has historically explored and developed natural gas and crude oil properties in the Rocky Mountain region. The Company currently has development activities and opportunities in its Atlantic Rim coalbed methane and in the Pinedale Anticline in Wyoming.  Also, exploration potential exists in its Niobrara acreage in Wyoming and Nebraska, which totals over 70,000 net acres, and over 6,000 net acres in Nevada. New focus areas include international and midstream opportunities that are currently being actively pursued.

This release may contain forward-looking statements regarding the Company’s future and expected performance based on assumptions that the Company believes are reasonable. No assurances can be given that these statements will prove to be accurate. A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, decreases in prices for natural gas and crude oil, unexpected decreases in gas and oil production, the timeliness, costs and results of development and exploration activities, unanticipated delays and costs resulting from regulatory compliance, and other risk factors described from time to time in the Company’s Forms 10-K and 10-Q and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
John Campbell, IR
(303) 794-8445
www.dble.com

Tuesday, March 25th, 2014 Uncategorized Comments Off on (DBLE) Petroleum Appoints Charles F. Chambers CEO